Desvenlafaxine | O-Desmethylvenlafaxine;DVS 233;MDD-XR;(±)-O-Desmethyl Venlafaxine;WY 45233 Succinate | o-去甲文拉法辛 | 5-HT Receptor | SSRIs

首页 / 抑制剂/激动剂 / / / Desvenlafaxine/去甲文拉法辛

Desvenlafaxine/去甲文拉法辛 {[allProObj[0].p_purity_real_show]}

货号：A105155 同义名： o-去甲文拉法辛 / O-Desmethylvenlafaxine; DVS 233

Desvenlafaxine inhibits serotonin(5-HT) and norepinephrine (NE) reuptake with Ki of 40.2 nM and 558.4 nM, respectively.

Desvenlafaxine/去甲文拉法辛化学结构
CAS号：93413-62-8

Desvenlafaxine/去甲文拉法辛 3D分子结构
CAS号：93413-62-8

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]}	现货	1周咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Desvenlafaxine/去甲文拉法辛纯度/质量文件产品仅供科研

货号：A105155 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Nature, 2025, 645, 793-800. Ambeed. [ A201204 , A444152 , A344107 , A952055 ]; • Cell, 2025. Ambeed. [ A122167 ]; • Science, 2025, 387(6729): eadp5637. Ambeed. [ A875019 ]; • Sig. Transduct. Target. Ther., 2025, 10, 257. Ambeed. [ A104916 ]; • Nat. Nanotechnol., 2025. Ambeed. [ A243018 , A1216705 , A522597 , A125401 , A1355641 ]; 更多 >

5-羟色胺受体亚型比较

产品名称	5-HT ↓ ↑	5-HT1 ↓ ↑	5-HT2 ↓ ↑	5-HT3 ↓ ↑	5-HT5 ↓ ↑	5-HT6 ↓ ↑	5-HT7 ↓ ↑	其他靶点	纯度
Desvenlafaxine	++ 5-HT, Ki: 40.2 nM								98%
Lamotrigine	+ 5-HT (rat brain synaptosomes), IC50: 474 μM 5-HT (human platelets), IC50: 240 μM								98%
Venlafaxine	✔								99%
Fluvoxamine maleate	✔								99%
Iloperidone	✔								99%
Ziprasidone HCl	✔								98+%
Atomoxetine HCI	+ 5-HT, Ki: 77 nM								98%
Dapoxetine HCl	✔								97%
Trazodone	✔								98+%
Clomipramine HCl	✔								98%
Mirtazapine	✔								99+%
Escitalopram oxalate	+++ 5-HT, Ki: 0.89 nM								97%
Duloxetine	✔								97%
Sertraline HCl	++ 5-HT, Ki: 13 nM								98%
Citalopram HBr	+++ serotonin reuptake, IC50: 1.8 nM								98%
Latrepirdine 2HCl	✔							GluR	99%
Fluoxetine HCl	✔								99.5%
Paroxetine HCl	✔							AChR	99%
BMY 7378		++ 5-HT1D, pIC50: 5.9 5-HT1A, pIC50: 6.4	+ 5-HT2, pIC50: 5.5						97%
Flibanserin		+++ 5-HT1A, Ki: 1 nM	+ 5-HT2A, Ki: 49 nM						95%
LY310762		+ 5-HT1D, Ki: 249 nM							99%+
Cyclobenzaprine HCI			✔						99%
Blonanserin			+++ 5-HT2, Ki: 3.98 nM						99%
Cyproheptadine HCl			++++ 5-HT2, IC50: 0.6 nM						99+%
Olanzapine			✔						99+%
Pimavanserin hemitartrate			+++ 5-HT2A, pIC50: 8.7						99%
Ketanserin			+++ 5-HT2C (Rat), Ki: 50 nM 5-HT2C (Human), Ki: 2.5 nM						99%+
Loxapine succinate			++ 5-HT2 (human), Ki: 6.8 nM 5-HT2 (bovine), Ki: 6.6 nM						98%
Agomelatine			✔						98%
Clozapine			✔						98%
Amitriptyline			+ 5-HT2, Ki: 235 nM					SERT	99%
PRX-08066 maleate			+++ 5-HT2B, IC50: 3.4 nM						98+%
RS-127445			++++ 5-HT2B, pIC50: 10.4 5-HT2B, pKi: 9.5						99%+
Sarpogrelate HCl			++++ 5-HT2A, Kd: 2.1 nM 5-HT2C, Kd: 1.1 nM						98%
Tropisetron				✔					99%
Ramosetron HCl				++++ 5-HT3 receptor, Ki: 0.091 nM					98%
Ondansetron				✔					99%
Granisetron				✔					98%
Alosetron HCl				✔					98%
Ondansetron HCl dihydrate				✔					98%
VUF10166				++++ 5-HT3AB, Ki: 22 nM 5-HT3A, Ki: 0.04 nM					99%+
Azasetron HCl				++++ 5-HT3, IC50: 0.33 nM					99%
Asenapine maleate		+++ 5-HT1B, pKi: 8.4 5-HT1A, pKi: 8.6	++++ 5-HT2C, pKi: 10.46 5-HT2A, pKi: 9.75		+++ 5-HT5A, pKi: 8.84	++++ 5-HT6, pKi: 9.6	++++ 5-HT7, pKi: 9.94		97%
Risperidone		++ 5-HT1B, Ki: 14.9 nM 5-HT1D, Ki: 84.6 nM	++++ 5-HT2A, Ki: 61.9 nM 5-HT2C, Ki: 12 nM		+ 5-HT5A, Ki: 206 nM		++ 5-HT7, Ki: 6.6 nM		98%
SB 271046 HCl						+++ 5-HT6, pKi: 8.92			99%+
Intepirdine						++++ 5-HT6, pKi: 9.63			99%+
SB-269970 HCl							++ 5-HT7, pKi: 8.3		98+%
BRL 15572		++ 5-HT1D, pKi: 6 5-HT1B, pKi: 6.1	++ 5-HT2A, pKi: 6.6 5-HT2B, pKi: 6.2			+ 5-HT6, pKi: 5.9	+ 5-HT7, pKi: 6.3		95%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Desvenlafaxine/去甲文拉法辛生物活性

靶点

5-HT

5-HT, Ki:40.2 nM

描述

Biogenic amines such as serotonin (5-HT), norepinephrine (NE), and dopamine (DA) are neurotransmitters found in areas of the central nervous system (CNS) known to be important for regulation of cognitive function, mood, thermo-regulation, pain sensation, sexual function, and various aspects of endocrine function related to homeostasis. Desvenlafaxine exhibits inhibitory activity of serotonin (5-HT) and norepinephrine (NE) reuptake with K_i of 40.2 and 558.4 nM, respectively. Desvenlafaxine inhibited the uptake of [³H]5-HT at the hSERT with a mean IC₅₀ value of 47.3 ± 19.4 nM. In addition, the IC₅₀ value of desvenlafaxine for [³H]NE uptake was 531.3 ± 113.0 nM. Acute oral administration of desvenlafaxine (30 mg/kg) did not significantly alter concentrations of 5-HT in the hypothalamus. However, pretreatment with WAY-100635 (5-HT_1A antagonist, 0.3 mg/kg s.c.), which did not alter 5-HT levels on its own, resulted in a significant 78% increase in extracellular 5-HT levels in the rat hypothalamus. In contrast, acute administration of desvenlafaxine, when given alone, produced a significant increase in NE concentrations^[3]. The response and remission rates of depression at 8 weeks for the 50-mg dose of desvenlafaxine are 51-63% and 31-45%, respectively^[4].

Desvenlafaxine/去甲文拉法辛临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT00797966	Major Depressive Disorder	Phase 2	Completed	-	-
NCT00797966	-		Completed	-	-
NCT01916824	Major Depressive Disorder ... 展开 >> Healthy Controls 收起 <<	Phase 4	Completed	-	United States, Georgia ... 展开 >> Emory Mood and Anxiety Disorders Program Atlanta, Georgia, United States, 30322 收起 <<

Desvenlafaxine/去甲文拉法辛参考文献

[1]Sopko MA Jr, Ehret MJ, Grgas M. Desvenlafaxine: another "me too" drug? Ann Pharmacother. 2008 Oct;42(10):1439-46.

[2]Deecher DC, Beyer CE, et al.Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2006 Aug;318(2):657-65.

[3]Deecher DC, Beyer CE, Johnston G, et al. Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2006;318(2):657‐665

[4]Sopko MA Jr, Ehret MJ, Grgas M. Desvenlafaxine: another "me too" drug?. Ann Pharmacother. 2008;42(10):1439‐1446

Desvenlafaxine/去甲文拉法辛实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

3.80mL

0.76mL

0.38mL

18.98mL

3.80mL

1.90mL

37.97mL

7.59mL

3.80mL

Desvenlafaxine/去甲文拉法辛技术信息

CAS号	93413-62-8
分子式	C₁₆H₂₅NO₂
分子量	263.38
SMILES Code	C1=CC(=CC=C1O)C(CN(C)C)C2(CCCCC2)O
MDL No.	MFCD00871934

别名	o-去甲文拉法辛 ;O-Desmethylvenlafaxine; DVS 233; MDD-XR; (±)-O-Desmethyl Venlafaxine; WY 45233 Succinate
运输	蓝冰
InChI Key	KYYIDSXMWOZKMP-UHFFFAOYSA-N
Pubchem ID	125017

存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Inert atmosphere, room temperature

溶解方案

细胞实验：

DMSO: 50 mg/mL(189.84 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验：请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用；以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

方案二

方案三

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT00797966	Major Depressive Disorder	Phase 2	Completed	-	-
NCT00797966	-		Completed	-	-
NCT01916824	Major Depressive Disorder ... 展开 >> Healthy Controls 收起 <<	Phase 4	Completed	-	United States, Georgia ... 展开 >> Emory Mood and Anxiety Disorders Program Atlanta, Georgia, United States, 30322 收起 <<
NCT01916824	-		Completed	-	-
NCT01350921	Drug Drug Interaction	Phase 1	Completed	-	United States, Kansas ... 展开 >> Research Site Overland Park, Kansas, United States Sweden Research Site Uppsala, Sweden 收起 <<
NCT01469377	Major Depressive Disorder	Phase 2	Completed	-	-
NCT01469377	-		Completed	-	-
NCT01235338	Healthy	Phase 1	Completed	-	United States, Florida ... 展开 >> Clinical Pharmacology of Miami Miami, Florida, United States, 33014 收起 <<
NCT01235338	-		Completed	-	-
NCT00834249	-		Completed	-	-
NCT02400346	-		Completed	-	-
NCT02400346	Major Depression Disorder	Phase 3	Completed	-	-
NCT00834249	Healthy	Phase 1	Completed	-	Canada, Quebec ... 展开 >> Anapharm Inc. Montreal, Quebec, Canada, H3X 2H9 Anapharm Inc. Sainte-Foy, Quebec, Canada, GIV2K8 收起 <<
NCT00834964	Healthy	Phase 1	Completed	-	Canada, Quebec ... 展开 >> Anapharm Inc. Montreal, Quebec, Canada, H3X 2H9 Anapharm Inc. Sainte-Foy, Quebec, Canada, GIV2K8 收起 <<
NCT02054299	Drug Metabolism ... 展开 >> Membrane Transport 收起 <<	Phase 1	Completed	-	Germany ... 展开 >> Department of Clinical Pharmacology, University Medical Center Goettingen Goettingen, Germany, 37075 收起 <<
NCT00834964	-		Completed	-	-
NCT02893371	-		Enrolling by invitation	June 2019	United States, New Mexico ... 展开 >> Christophe G Lambert Albuquerque, New Mexico, United States, 87131 收起 <<
NCT02058693	Major Depressive Disorder	Phase 4	Completed	-	United States, Illinois ... 展开 >> Rush University Medical Center Chicago, Illinois, United States, 60612 收起 <<
NCT02637193	Healthy Subjects	Phase 1	Completed	-	United States, Connecticut ... 展开 >> Pfizer New Haven Clinical Research Unit New Haven, Connecticut, United States, 06511 收起 <<
NCT00767624	Sleep Initiation and Maintenan... 展开 >>ce Disorders Depression 收起 <<	Phase 2 Phase 3	Completed	-	United States, California ... 展开 >> Stanford University School of Medicine Stanford, California, United States, 94305 United States, North Carolina Duke University Durham, North Carolina, United States United States, Pennsylvania University of Pittsburgh Pittsburgh, Pennsylvania, United States 收起 <<
NCT00767624	-		Completed	-	-
NCT00421031	Vasomotor Symptoms	Phase 3	Completed	-	-
NCT00256685	Menopause Hot... 展开 >> Flashes Sleep Disorders 收起 <<	Phase 3	Completed	-	-
NCT01867255	Bariatric Surgery ... 展开 >> Gastric Bypass Roux-en-Y Gastric Bypass 收起 <<	Phase 1	Completed	-	United States, Minnesota ... 展开 >> Mayo Clinic in Rochester Rochester, Minnesota, United States, 55905 收起 <<
NCT01260896	Healthy	Phase 1	Completed	-	Canada, Quebec ... 展开 >> Anapharm Inc. Sainte-Foy, Quebec, Canada, G1V 2K8 收起 <<
NCT01260896	-		Completed	-	-
NCT01282801	-		Completed	-	-
NCT02320240	-		Completed	-	Canada, Quebec ... 展开 >> Lady Davis Institute for Medical Research, Jewish General Hospital Montreal, Quebec, Canada, H3T1E2 收起 <<
NCT00366652	Depression De... 展开 >>pressive Disorder Depressive Disorder, Major 收起 <<	Phase 3	Completed	-	United States, New Jersey ... 展开 >> Neptune, New Jersey, United States, 07753 收起 <<
NCT02055300	Major Depressive Disorder	Phase 1	Completed	-	United States, Ohio ... 展开 >> Medpace Cincinnati, Ohio, United States, 45227 收起 <<
NCT01282801	Healthy	Phase 1	Completed	-	Canada, Quebec ... 展开 >> Anapharm Inc. Sainte-Foy, Quebec, Canada, G1V 2K8 收起 <<
NCT00456898	Depressive Disorder, Major ... 展开 >> Diabetic Neuropathies Fibromyalgia Vasomotor Symptoms 收起 <<	Phase 1	Completed	-	-
NCT00283842	Diabetic Neuropathies ... 展开 >> Pain 收起 <<	Phase 3	Terminated(business reasons)	-	-
NCT02271412	Major Depressive Disorder, Rec... 展开 >>urrent, Unspecified 收起 <<	Phase 1	Completed	-	United States, New Jersey ... 展开 >> PRA Health Sciences Marlton, New Jersey, United States, 08053 收起 <<
NCT00329147	Depression	Phase 3	Completed	-	United States, New Jersey ... 展开 >> Neptune, New Jersey, United States, 07753 收起 <<
NCT00401245	Vasomotor Symptoms	Phase 3	Completed	-	-
NCT00445679	Depressive Disorder, Major	Phase 3	Completed	-	-
NCT00401245	-		Completed	-	-
NCT00283842	-		Terminated(business reasons)	-	-
NCT00445679	-		Completed	-	-
NCT00452595	Major Depressive Disorder	Phase 3	Completed	-	-
NCT00696787	-		Terminated	-	-
NCT00397176	Vasomotor Symptoms	Phase 1	Completed	-	-
NCT00424892	Fibromyalgia	Phase 2 Phase 3	Completed	-	-
NCT00696787	Fibromyalgia	Phase 2	Terminated	-	-
NCT00277823	Major Depressive Disorder	Phase 3	Completed	-	-
NCT01056289	Major Depressive Disorder	Phase 4	Completed	-	-
NCT01056289	-		Completed	-	-
NCT01050218	-		Terminated(Business reasons)	-	-
NCT02548949	-		Recruiting	September 2019	Korea, Republic of ... 展开 >> Chungbuk National University Hospital Recruiting Cheongju-si, Chungcheonbuk-do, Korea, Republic of, 362-711 Hallym University Sacred Heart Hospital Recruiting Anyang-Si, Gyeonggi-do, Korea, Republic of, 431-796 Inje University Ilsan Paik Hospital Recruiting Goyang-si, Gyeonggi-do, Korea, Republic of, 411-706 Bundang Cha Medical Center Recruiting Seongnam-si, Gyeonggi-do, Korea, Republic of, 13496 Bong Seng Memorial Hospital Recruiting Busan, Korea, Republic of, 601-723 Pusan National University Hospital Not yet recruiting Busan, Korea, Republic of, 602-739 Kyungpook National University Hospital Recruiting Daegu, Korea, Republic of, 700-721 Chungnam National University Hospital Recruiting Daejeon, Korea, Republic of, 301-721 Chungnam National University Hospital Not yet recruiting Daejeon, Korea, Republic of, 301-721 Chuncheon Sacred Heart Hospital-Hallym University Recruiting Gangwon-do, Korea, Republic of, 24253 Chosun University Hospital Recruiting Gwangju, Korea, Republic of, 61453 Chonnam National University Hospital Recruiting Gwangju, Korea, Republic of, 61469 Presbyterian Medical Center Recruiting Jeonju, Korea, Republic of, 560-750 Nowon Eulji Medical Center, Eulji University Recruiting Seoul, Korea, Republic of, 01830 Korea University Anam Hospital Recruiting Seoul, Korea, Republic of, 02841 Seoul National University Hospital Recruiting Seoul, Korea, Republic of, 03080 Hanyang University Seoul Hospital Recruiting Seoul, Korea, Republic of, 04763 Chung-Ang University Hospital Recruiting Seoul, Korea, Republic of, 06973 Konkuk University Medical Center Recruiting Seoul, Korea, Republic of, 143-729 收起 <<
NCT01372150	Major Depressive Disorder	Phase 3	Completed	-	-
NCT01050218	Diabetic Neuropathy, Painful	Phase 3	Terminated(Business reasons)	-	-
NCT01309542	Major Depressive Disorder	Phase 3	Completed	-	-
NCT01372150	-		Completed	-	-
NCT01371708	Major Depressive Disorder	Phase 3	Completed	-	-
NCT01371708	-		Completed	-	-
NCT01371721	-		Completed	-	-
NCT01371721	Major Depressive Disorder	Phase 3	Completed	-	-
NCT00406640	Depression De... 展开 >>pressive Disorder Depressive Disorder, Major 收起 <<	Phase 3	Completed	-	-
NCT00798707	-		Completed	-	-
NCT00406640	-		Completed	-	-
NCT01371734	-		Completed	-	-
NCT00798707	Major Depressive Disorder	Phase 3	Completed	-	-
NCT01371734	Major Depressive Disorder	Phase 3	Completed	-	-
NCT00369343	Depression De... 展开 >>pressive Disorder Depressive Disorder, Major 收起 <<	Phase 3	Completed	-	-
NCT00369343	-		Completed	-	-
NCT00369434	Menopause Vas... 展开 >>omotor System 收起 <<	Phase 3	Completed	-	-
NCT00727064	-		Completed	-	-
NCT01190514	Depression - Major Depressive ... 展开 >>Disorder 收起 <<	Phase 1	Completed	-	Belgium ... 展开 >> Pfizer Investigational Site Bruxelles, Belgium, B-1070 收起 <<
NCT01190514	-		Completed	-	-
NCT00727064	Healthy	Phase 1	Completed	-	United States, Kansas ... 展开 >> Clinical Research Institute Wichita, Kansas, United States, 67211 收起 <<
NCT00619619	Depression Ma... 展开 >>jor Depressive Disorder 收起 <<	Phase 2	Completed	-	United States, Arkansas ... 展开 >> Pfizer Investigational Site Little Rock, Arkansas, United States, 72205 United States, Florida Pfizer Investigational Site North Miami, Florida, United States, 33161 United States, Indiana Pfizer Investigational Site Terre Haute, Indiana, United States, 47802 United States, Kansas Pfizer Investigational Site Wichita, Kansas, United States, 67211 United States, Louisiana Pfizer Investigational Site New Orleans, Louisiana, United States, 70114 United States, New York Pfizer Investigational Site New York, New York, United States, 10032 United States, Ohio Pfizer Investigational Site Cleveland, Ohio, United States, 44106-5080 United States, Pennsylvania Pfizer Investigational Site Hershey, Pennsylvania, United States, 17033 United States, Texas Pfizer Investigational Site Houston, Texas, United States, 77008 收起 <<
NCT00619619	-		Completed	-	-
NCT00384033	-		Completed	-	-
NCT00384033	Depressive Disorder, Major	Phase 3	Completed	-	United States, California ... 展开 >> Pfizer Investigational Site Beverly Hills, California, United States, 90210 Pfizer Investigational Site Burbank, California, United States, 91506 Pfizer Investigational Site Encino, California, United States, 91316 Pfizer Investigational Site Los Alamitos, California, United States, 90720 Pfizer Investigational Site Newport Beach, California, United States, 92660 Pfizer Investigational Site Northridge, California, United States, 91324 Pfizer Investigational Site Orange, California, United States, 92868 Pfizer Investigational Site Pasadena, California, United States, 91105 Pfizer Investigational Site Upland, California, United States, 91786 United States, Florida Pfizer Investigational Site South Miami, Florida, United States, 33143 Pfizer Investigational Site St. Petersburg, Florida, United States, 33702 United States, Illinois Pfizer Investigational Site Edwardsville, Illinois, United States, 62025 United States, Michigan Pfizer Investigational Site Farmington Hills, Michigan, United States, 48336 Pfizer Investigational Site Flint, Michigan, United States, 48507 Pfizer Investigational Site Okemos, Michigan, United States, 48864 United States, New Jersey Pfizer Investigational Site Clementon, New Jersey, United States, 08021 United States, Ohio Pfizer Investigational Site Dayton, Ohio, United States, 45408 United States, Oregon Pfizer Investigational Site Portland, Oregon, United States, 97210 United States, Pennsylvania Pfizer Investigational Site Philadelphia, Pennsylvania, United States, 19149 United States, Utah Pfizer Investigational Site Salt Lake City, Utah, United States, 84107 United States, Washington Pfizer Investigational Site Seattle, Washington, United States, 98104 United States, Wisconsin Pfizer Investigational Site Brown Deer, Wisconsin, United States, 53223 收起 <<
NCT00863798	Major Depressive Disorder	Phase 3	Completed	-	United States, Alabama ... 展开 >> Pfizer Investigational Site Birmingham, Alabama, United States, 35216 United States, California Pfizer Investigational Site Encino, California, United States, 91316 Pfizer Investigational Site Newport Beach, California, United States, 92660 Pfizer Investigational Site Redlands, California, United States, 92374 Pfizer Investigational Site Upland, California, United States, 91786 United States, Colorado Pfizer Investigational Site Aurora, Colorado, United States, 80045 Pfizer Investigational Site Denver, Colorado, United States, 80204 United States, Connecticut Pfizer Investigational Site Cromwell, Connecticut, United States, 06416 United States, Florida Pfizer Investigational Site Maitland, Florida, United States, 32751 Pfizer Investigational Site North Miami, Florida, United States, 33161 Pfizer Investigational Site South Miami, Florida, United States, 33143 United States, Indiana Pfizer Investigational Site Indianapolis, Indiana, United States, 46260 United States, Missouri Pfizer Investigational Site St. Louis, Missouri, United States, 63139 United States, New York Pfizer Investigational Site New York, New York, United States, 10128 Pfizer Investigational Site Staten Island, New York, United States, 10312 United States, Ohio Pfizer Investigational Site Toledo, Ohio, United States, 43623 United States, Oregon Pfizer Investigational Site Eugene, Oregon, United States, 97401 Pfizer Investigational Site Portland, Oregon, United States, 97210 Pfizer Investigational Site Salem, Oregon, United States, 97301 United States, Pennsylvania Pfizer Investigational Site Media, Pennsylvania, United States, 19063 United States, Virginia Pfizer Investigational Site Herndon, Virginia, United States, 20170 Pfizer Investigational Site Midlothian, Virginia, United States, 23112 United States, Wisconsin Pfizer Investigational Site Middleton, Wisconsin, United States, 53562 Pfizer Investigational Site Waukesha, Wisconsin, United States, 53188 收起 <<
NCT00440427	Depressive Disorder, Major	Phase 1	Completed	-	United States, Massachusetts ... 展开 >> Boston, Massachusetts, United States, 02135 收起 <<
NCT00329186	Healthy	Phase 3	Completed	-	United States, Kansas ... 展开 >> Wichita, Kansas, United States, 67207 收起 <<
NCT00863798	-		Completed	-	-
NCT00300378	Depressive Disorder, Major	Phase 3	Completed	-	-
NCT01468610	Major Depressive Disorder	Not Applicable	Completed	-	Canada, British Columbia ... 展开 >> University of British Columbia, Department of Psychiatry Vancouver, British Columbia, Canada, V6T 2A1 收起 <<
NCT00683800	-		Completed	-	-
NCT00683800	Vasomotor Symptoms	Phase 3	Completed	-	-
NCT00669110	Depressive Disorder, Major Dep... 展开 >>ressive Disorder 收起 <<	Phase 2	Completed	-	United States, Arkansas ... 展开 >> Pfizer Investigational Site Little Rock, Arkansas, United States, 72205 United States, Florida Pfizer Investigational Site North Miami, Florida, United States, 33161 United States, Indiana Pfizer Investigational Site Terre Haute, Indiana, United States, 47802 United States, Kansas Pfizer Investigational Site Wichita, Kansas, United States, 67211 United States, Louisiana Pfizer Investigational Site New Orleans, Louisiana, United States, 70114 United States, New York Pfizer Investigational Site New York, New York, United States, 10032 United States, Ohio Pfizer Investigational Site Cleveland, Ohio, United States, 44106 United States, Pennsylvania Pfizer Investigational Site Hershey, Pennsylvania, United States, 17033 United States, Texas Pfizer Investigational Site Houston, Texas, United States, 77008 收起 <<
NCT00952653	-		Completed	-	-
NCT00669110	-		Completed	-	-
NCT00952653	Major Depressive Disorder	Phase 4	Completed	-	United States, Connecticut ... 展开 >> Pfizer Investigational Site New Haven, Connecticut, United States, 06511 收起 <<
NCT00887224	Major Depressive Disorder	Phase 3	Completed	-	-
NCT01221935	-		Completed	-	-
NCT00887224	-		Completed	-	-
NCT02330679	Major Depressive Disorder	Phase 4	Unknown	December 2016	Canada, Alberta ... 展开 >> University of Calgary, TRW Building, Foothills Hospital Campus Recruiting Calgary, Alberta, Canada, T2N4Z6 Contact: Rajamannar Ramasubbu, MD, FRCP(C) 403-210-6890 rramasub@ucalgary.ca Contact: Darren Clark, PhD 403-210-6353 dlclark@ucalgary.ca Principal Investigator: Rajamannar Ramasubbu, MD, FRCP(C) University of Calgary: Foothills Hospital Recruiting Calgary, Alberta, Canada, T2N4Z6 Principal Investigator: Rajamannar Ramasubbu, MD, FRCP(C) 收起 <<
NCT01121484	Major Depressive Disorder	Phase 4	Completed	-	-
NCT01492621	Major Depression	Phase 4	Unknown	November 2013	Canada, Quebec ... 展开 >> Centre de Recherche Fernand-Seguin Recruiting Montreal, Quebec, Canada, H1N3V2 Contact: Souad Lahlafi, Bnurs 5142514000 ext 3416 slahlafi.crfs@ssss.gouv.qc.ca Contact: Louise Normandeau, Nurs 5142514000 ext 3535 lnormandeau.hlhl@ssss.gouv.qc.ca 收起 <<
NCT01975480	Generalized Anxiety Disorder	Phase 4	Recruiting	August 1, 2018	Canada, Ontario ... 展开 >> START Clinic for Mood and Anxiety Disorders Recruiting Toronto, Ontario, Canada, M4W 2N4 Contact: Martin A Katzman, BSc, MD, FRCPC 416-598-9344 mkatzman@startclinic.ca Principal Investigator: Martin A Katzman, BSc 收起 <<
NCT01101152	Healthy	Phase 1	Unknown	December 2011	Canada, Ontario ... 展开 >> University of Ottawa Institute of Mental Health Research Recruiting Ottawa, Ontario, Canada, K1Z 7K4 Contact: Olga Chernoloz, B.Sc.Pharm 613-722-6521 ext 6405 olga.chernoloz@rohcg.on.ca Principal Investigator: Pierre Blier, M.D., Ph.D. 收起 <<
NCT00824291	Depressive Disorder, Major	Phase 3	Completed	-	-
NCT01121484	-		Completed	-	-
NCT01803711	Major Depression ... 展开 >> Cancer Diabetes Cardiovascular Diseases 收起 <<	Phase 2 Phase 3	Terminated(Lack of recruitment... 展开 >> and no resources) 收起 <<	-	United States, Connecticut ... 展开 >> University of Connecticut Health Center Farmington, Connecticut, United States, 06030 收起 <<
NCT00824291	-		Completed	-	-
NCT01189500	Pharmacokinetics	Phase 4	Completed	-	United States, Florida ... 展开 >> Pfizer Investigational Site Miami, Florida, United States, 33126 Pfizer Investigational Site Miami, Florida, United States, 33134 收起 <<
NCT01803711	-		Terminated(Lack of recruitment... 展开 >> and no resources) 收起 <<	-	-
NCT01443208	Major Depressive Disorder	Phase 1	Completed	-	Korea, Republic of ... 展开 >> Pfizer Investigational Site Seoul, Korea, Republic of, 110-744 收起 <<
NCT01189500	-		Completed	-	-
NCT01432457	Major Depressive Disorder	Phase 4	Completed	-	-
NCT00831415	-		Completed	-	-
NCT00831415	Major Depressive Disorder	Phase 3	Completed	-	Japan ... 展开 >> Pfizer Investigational Site Aichi, Japan Pfizer Investigational Site Chiba, Japan Pfizer Investigational Site Fukuoka, Japan Pfizer Investigational Site Fukushima, Japan Pfizer Investigational Site Gunma, Japan Pfizer Investigational Site Hiroshima, Japan Pfizer Investigational Site Hokkaido, Japan Pfizer Investigational Site Hyogo, Japan Pfizer Investigational Site Ishikawa, Japan Pfizer Investigational Site Kanagawa, Japan Pfizer Investigational Site Kumamoto, Japan Pfizer Investigational Site Kyoto, Japan Pfizer Investigational Site Osaka, Japan Pfizer Investigational Site Saga, Japan Pfizer Investigational Site Saitama, Japan Pfizer Investigational Site Shiga, Japan Pfizer Investigational Site Tokyo, Japan 收起 <<
NCT01977378	Major Depressive Disorder	Phase 2 Phase 3	Unknown	-	China, Guangdong ... 展开 >> Guangdong General Hospital Recruiting Guangzhou, Guangdong, China China, Hunan The Second Xiangya Hospital of Central South University Recruiting Changsha, Hunan, China China, Sichuan West China Hospital Recruiting Chengdu, Sichuan, China China Beijing An Ding Hospital Recruiting Beijing, China, 100088 Beijing HuiLongGuan Hospital Recruiting Beijing, China, 100096 The Shanghai Mental Health Recruiting Shanghai, China, 200030 Contact: Huafang Li, Professor 86-021-34773128 lhlh_5@163.com Principal Investigator: Huafang Li, Professor 收起 <<
NCT01432457	-		Completed	-	-
NCT01316302	-		Completed	-	-
NCT01353963	-		Terminated	-	Philippines ... 展开 >> Private Clinic Las Pinas, Philippines Private Clinic Manila, Philippines Private Clinic Pasay City, Philippines 收起 <<
NCT01527786	Depression	Phase 3	Completed	-	Canada, British Columbia ... 展开 >> BC Women's Hospital Vancouver, British Columbia, Canada, V6H 3N1 收起 <<
NCT01353963	-		Terminated	-	-
NCT01316302	Social Anxiety Disorder	Phase 4	Completed	-	United States, New York ... 展开 >> The Medical Research Network, LLC New York, New York, United States, 10128 收起 <<
NCT00818155	Healthy	Phase 1	Completed	-	-
NCT01537068	Dysthymic Disorder ... 展开 >> Dysthymia Chronic Depressive Disorder 收起 <<	Phase 4	Completed	-	United States, New York ... 展开 >> New York State Psychiatric Institute/3 Columbus Circle Midtown New York, New York, United States, 10019 Depression Evaluation Service (DES), New York State Psychiatric Institute, Columbia University Department of Psychiatry New York, New York, United States, 10032 收起 <<
NCT01188668	-		Completed	-	-
NCT02988024	Major Depression	Phase 1	Completed	-	United States, New Jersey ... 展开 >> Clinilabs, Inc. Eatontown, New Jersey, United States, 07724 收起 <<
NCT01537068	-		Completed	-	-
NCT01188668	Pharmacokinetics ... 展开 >> Cytochrome P-450 CYP2D6 CYP3A4 Protein, Human 收起 <<	Phase 4	Completed	-	United States, Florida ... 展开 >> Pfizer Investigational Site Miami, Florida, United States, 33126 Pfizer Investigational Site Miami, Florida, United States, 33134 收起 <<
NCT03432221	-		Not yet recruiting	April 3, 2019	-
NCT00888862	Major Depressive Disorder ... 展开 >> Menopausal Staging and Vasomotor Symptoms (for Females) 收起 <<	Phase 3	Unknown	October 2012	Canada, Ontario ... 展开 >> Women's Health Concerns Clinic Recruiting Hamilton, Ontario, Canada, L8P 3B6 Contact: Stefanie M Attard 905-522-1155 ext 32048 sattard@stjoes.ca Principal Investigator: Claudio N Soares, MD, PhD Sub-Investigator: Benicio N Frey, MD, PhD Sub-Investigator: Geoff Hall, PhD Sub-Investigator: Meir Steiner, MD, PhD 收起 <<
NCT02859103	Depression An... 展开 >>hedonia 收起 <<	Phase 4	Recruiting	January 2019	Canada, Ontario ... 展开 >> St. Michael's Hospital Recruiting Toronto, Ontario, Canada, M5B 1M8 Contact: Troy Chow, HBSc 416-864-6060 ext 7844 chowt@smh.ca Principal Investigator: Sakina Rizvi, PhD 收起 <<
NCT02819921	Hot Flashes B... 展开 >>reast Neoplasms 收起 <<	Phase 4	Recruiting	December 2020	Korea, Republic of ... 展开 >> National Cancer Center Recruiting Goyang, Gyeonggi-do, Korea, Republic of, 10408 Contact: Hyun-Jung Lee, M.D. Principal Investigator: Hyun-Jung Lee, M.D. Seoul National University Bundang Hospital Not yet recruiting Seongnam, Gyeonggi-do, Korea, Republic of, 13620 Contact: Jeong-Hyun Kim, M.D., Ph.D. Principal Investigator: Jeong-Hyun Kim, M.D., Ph.D. Seoul National University Hospital Recruiting Seoul, Korea, Republic of, 03080 Contact: Kyung-Lak Son, M.D. 82-02-2072-3767 klson01@gmail.com 收起 <<
NCT03733574	Major Depressive Disorder	Phase 1	Completed	-	United States, Maryland ... 展开 >> Pharmaron CPC, Inc. Baltimore, Maryland, United States, 21201 收起 <<
NCT01974934	Vascular Depression	Phase 4	Unknown	-	Canada, Ontario ... 展开 >> Hotel-Dieu Grace Healthcare Recruiting Windsor, Ontario, Canada, N9C 3Z4 Contact: Jeff Geml jeff.geml@hdgh.org Principal Investigator: Corina Velehorschi, MD 收起 <<
NCT01948895	Dysthymic Disorder	Not Applicable	Completed	-	Canada, Ontario ... 展开 >> Medical Research Associates Mississauga, Ontario, Canada, L5M 4N4 Centre for Addiction and Mental Health Toronto, Ontario, Canada, M5T 1R8 收起 <<
NCT03357796	Major Depressive Disorder	Phase 1	Completed	-	United States, New Jersey ... 展开 >> Clinilabs, Inc. Eatontown, New Jersey, United States, 07724 收起 <<
NCT02200406	Depression Op... 展开 >>ioid Dependence Methadone Treatment 收起 <<	Phase 4	Completed	-	Canada, Quebec ... 展开 >> Centre de recherche du Centre Hospitalier de l'Université de Montréal Montréal, Quebec, Canada, H2X0A9 收起 <<

Desvenlafaxine/去甲文拉法辛 {[allProObj[0].p_purity_real_show]}

Desvenlafaxine/去甲文拉法辛纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Desvenlafaxine/去甲文拉法辛质控信息

Desvenlafaxine/去甲文拉法辛生物活性

Desvenlafaxine/去甲文拉法辛临床研究

Desvenlafaxine/去甲文拉法辛参考文献

Desvenlafaxine/去甲文拉法辛实验方案

Desvenlafaxine/去甲文拉法辛技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Desvenlafaxine/去甲文拉法辛 {[allProObj[0].p_purity_real_show]}

Desvenlafaxine/去甲文拉法辛 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Desvenlafaxine/去甲文拉法辛 质控信息

Desvenlafaxine/去甲文拉法辛 生物活性

Desvenlafaxine/去甲文拉法辛 临床研究

Desvenlafaxine/去甲文拉法辛 参考文献

Desvenlafaxine/去甲文拉法辛 实验方案

Desvenlafaxine/去甲文拉法辛 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Desvenlafaxine/去甲文拉法辛纯度/质量文件产品仅供科研

Desvenlafaxine/去甲文拉法辛质控信息

Desvenlafaxine/去甲文拉法辛生物活性

Desvenlafaxine/去甲文拉法辛临床研究

Desvenlafaxine/去甲文拉法辛参考文献

Desvenlafaxine/去甲文拉法辛实验方案

Desvenlafaxine/去甲文拉法辛技术信息